Provigil was approved for narcolepsy in late 1998, which only affects around 200,000 people in the US, according to a July 2010 report by Global Industry Analysts.
US sales began in February 1999. Ten months later, "25% of narcolepsy patients in the country, more than 31,000 people, were taking the drug. It generated $25 million in 1999 sales, and Cephalon's revenue nearly tripled to $45 million," according to an August 1, 2000 report, by Matthew Herper, on Forbes.com.
A November 20, 2002, New York Times article reported that Cephalon CEO, Frank Baldino, himself, was taking Provigil, but would not say what condition he used it for. Provigil is short for "promotes vigilance," according to the Times.
(Note: You can view every article as one long page if you sign up as an Advocate Member, or higher).